Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 9, Issue 5, Pages 825-837Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.9.5.825
Keywords
aliskiren; direct renin inhibitors; hypertension; renin-angiotensin-aidosterone system
Categories
Ask authors/readers for more resources
Background: Aliskiren, the first renin inhibitor with sufficient bioavailability for oral use, is now available to clinicians treating hypertension. Objective: The novel mechanism by which aliskiren works was used to provide understanding of its therapeutic and adverse effects. Methods: After reviewing physiology and preclinical studies, human studies of aliskiren in hypertension were reviewed. Effects of aliskiren on serum levels and enzymatic activity of renin were explored. Results/conclusions: Aliskiren has antihypertensive efficacy similar to existing medications such as thiazide diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and can be used in drug combinations. Preclinical studies indicate possible cardioprotective and renoprotective effects, similar to other inhibitors of the renin-angiotensin cascade, but future studies are needed in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available